Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1287-1296

  De Jong, Jill L O ^a   Farner, Nancy L ^a   Javorsky, Bradley R ^a   Lindstrom, Mary J ^b   Hank, Jacquelyn A ^a   Sondel, Paul M ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F 42K; INTERLEUKIN 2; INTERLEUKIN 2 DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH14 18; MONOCLONAL ANTIBODY R24; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TARGET CELL;

ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; MELANOMA; TUMOR CELLS, CULTURED;

EID: 0031925166     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sondel, P. M., Kohler, P. C., Hank, J. A., Moore, K. H., Rosenthal, N. S., Sosman, J. A., Bechhofer, R., and Storer, B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res., 48: 2561-2567, 1988.
2. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc., 271: 907-913, 1994.
3. Damle, N. K., Doyle, L. V., Bender, J. R., and Bradley, E. C. IL-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol., 138: 1779-1785, 1987.
4. Sondel, P. M., Hank, J. A., Kohler, P. C., Chen, B. P., Minkoff, D. Z., and Molenda, J. A. Destruction of autologous human lymphocytes by interleukin-2 activated cytotoxic cells. J. Immunol., 137: 502-511, 1986.
5. Lotze, M. T., Chang, A. E., Seipp, C. A., Simpson, C., Vetto, J. T., and Rosenberg, S. A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. J. Am. Med. Assoc., 256: 3117-3124, 1986.
6. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
7. Siegel, J. P., and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
8. Weil-Hillman, G., Voss, S. D., Fisch, P., Schell, K., Hank, J. A., Sosman, J. A., Sugamura, K., and Sondel, P. M. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res., 50: 2683-2691, 1990.
9. Hank, J. A., Weil-Hillman, G., Surfus, J. E., Sosman, J. A., and Sondel, P. M. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol. Immunother., 31: 53-59, 1990.
10. Hank, J. A., Kohler, P. C, Weil-Hillman, G., Rosenthal, N., Moore, K. H., Storer, B., Minkoff, D., Bradshaw, J., Bechhofer, R., and Sondel, P. M. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res., 48: 1965-1971, 1988.
11. Hank, J. A., Sosman, J. A., Kohler, P. C., Bechhofer, R., Storer, B., and Sondel, P. M. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J. Biol. Resp. Modif., 9: 5-14, 1990.
12. Voss, S. D., Sondel, P. M., and Robb, R. J. Characterization of the interleukin-2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2Rγ chain with the IL-2Rβ chain in functional intermediate affinity IL-2R. J. Exp. Med., 176: 531-541, 1992.
13. Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R., and Grabstein, K. H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol., 154: 483-490, 1995.
14. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenman, J., Grabstein, K., and Caligiuri, M. A. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med., 180: 1395-1403, 1994.
15. Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine, IL-15. EMBO J., 13: 2822-2830, 1994.
16. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science (Washington DC), 264: 965-968, 1994.
17. Carson, W. E., Ross, M. E., Baiocchi, R. A., Marien, M. J., Boiani, N., Grabstein, K., and Caligiuri, M. A. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J. Clin. Invest., 96: 2578-2582, 1995.
18. Kumaki, S., Armitage, R., Ahdieh, M., Park, L., and Cosman, D. Interleukin-15 up-regulates interleukin-2 receptor α chain but down-regulates its own high-affinity binding sites on human T and B cells. Eur. J. Immunol., 26: 1235-1239, 1996.
19. Konrad, M. W., De Witt, S. K., Bradley, E. C., Goodman, G., Groves, E. C., Hersh, E. M., Krigel, R. L., and Randolph, A. Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer: kinetics, dose dependence, and correlation with physiologic and therapeutic response. J. Immunother., 12: 55-63, 1992.
20. Martin, S., Manita, K., Burkart, V., Gillis, S., and Kolb, H. IL-1 and IFN-γ increase vascular permeability. Immunology, 64: 301-305, 1988.
21. Fraker, D. L., Langstein, H. N., and Norton, J. A. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J. Exp. Med., 770: 1015-1020, 1989.
22. Economou, J. S., Hoban, M., Lee, J. D., Essner, R., Swisher, S., McBride, W., Hoon, D. B., and Morton, D. L. Production of tumor necrosis factor-α and Interferon-γ in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol. Immunother., 34: 49-52, 1991.
23. Lewko, W. M., Smith, T. L., Bowman, D. J., Good, R. W., and Oldham, R. K. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother., 10: 13-20, 1995.
24. Munger, W., DeJoy, S. Q., Jeyaseelan, R., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxton, R., Cox, T., Wick, M. M., and Kerwar, S. S. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol., 165: 289-293, 1995.
25. Sauvé, K., Nachman, M., Spence, C., Bailon, P., Campbell, E., Tsien, W-H., Kondas, J. A., Hakimi, J., and Ju, G. Localization in human interleukin 2 of the binding site to the α chain (p55) of the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 88: 4636-4640, 1991.
26. Grant, A., Roessler, E., Ju, G., Tsudo, M., Sugamura, K., and Waldmann, T. The interleukin 2 receptor (IL-2R): the IL-2Rα subunit alters the function of the IL-2Rβ subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to the IL-2Rα subunit. Proc. Natl. Acad. Sci. USA, 89: 2165-2169, 1992.
27. Roessler, E., Grant, A., Ju, G., Tsudo, M., Sugamura, K., and Waldmann, T. A. Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits. Proc. Natl. Acad. Sci. USA, 91: 3344-3347, 1994.
28. Albertini, M. R., Hank, J. A., Schiller, J. H., Koursand, M., Borchert, A. A., Gan, J., Bechhofer, R., Storer, B., Reisfeld, R. A., and Sondel, P. M. A Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res., 3: 1277-1288, 1997.
29. De Maria, R., Cifone, M. G., Trotta, R., Rippo, M. R., Festuccia, C., Santoni, A., and Testi, R. Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. J. Exp. Med., 180: 1999-2004, 1994.
30. Gerosa, F., Tommasi, M., Benati, C., Gandini, G., Libonati, M., Tridente, G., Carra, G., and Trinchieri, G. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-α in human NK cells. Cell. Immunol., 150: 382-390, 1993.
31. Testi, R., D'Ambrosio, D., De Maria, R., and Santoni, A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today, 15: 479-483, 1994.
32. Mardiney, M., III, Brown, M. R., and Fleisher, T. A. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen-or antigen-induced proliferative capacity in normals. Cytometry, 26: 305-310, 1996.
33. c receptor-ligand complex. J. Immunol., 156: 1339-1348, 1996.
34. Welte, B., Handgretinger, R., Rassner, G., and Fierlbeck, G. Expression of GD3 disialoganglioside antigen on peripheral T-lymphocytes in patients with disseminated malignant melanoma. Exp. Dermatol., 6: 64-69, 1997.
35. + natural killer cells. Eur. J. Immunol., 24: 1208-1212, 1994.